Aquestive Therapeutics, Inc. (AQST): Revenue
$44.55M
Year ended 2025-12-31
$54.09M
Trailing 12 months to 2026-06-30
-2.2%
3-year compound annual growth
-0.6%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.55M | -22.6% | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | $57.56M | +13.8% | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | $50.58M | +6.1% | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | $47.68M | -6.2% | 2024-03-05, From 2022-01-01 |
| 2021-12-31 | $50.83M | +10.9% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $45.85M | -12.8% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $52.61M | -22.0% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $67.43M | +0.8% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $66.92M | n/a | 2019-03-14, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $44.55M | -22.6% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $44.52M | +17.6% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $43.87M | -19.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $43.77M | +589.9% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $45.95M | n/m |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $46.02M | -89.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $42.73M | -60.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $41.70M | +11.7% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $48.47M | -57.7% |
Compare AQST, CPIX, INBP, XLO side by side · Screen every company in Pharmaceutical Preparations ↗